Skip to main content

BioCardia, Inc 8-K, filed Jun 15, 2021

BioCardia, Inc. (BCDA)

8-K 2021-06-15 For: 2021-06-15
View Original
Added on April 06, 2026

About this 8-K

BioCardia, Inc filed this 8-K on June 15, 2021.

Items reported

  • Item 5.07: Shareholder vote results

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 15, 2021

BIOCARDIA, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-21419 23-2753988
--- --- ---
(State or other jurisdiction<br><br> <br>of incorporation) (Commission<br><br> <br>File Number) (IRS Employer<br><br> <br>Identification No.)
125 Shoreway Road, Suite B <br> San Carlos, California 94070
---
(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (650) 226-0120

_____________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
--- ---
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
--- ---
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
--- ---
Title of each class Trading Symbol(s) Name of each exchange on which registered
--- --- ---
Common Stock, par value $0.001 BCDA The Nasdaq Capital Market
Warrant to Purchase Common Stock BCDAW The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter) ☐<br><br> <br><br><br> <br><br><br> <br>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
---

Item 5.07         Submission of Matters to a Vote of Security Holders.

On June 15, 2021, the Company held its Annual Meeting. Present at the Annual Meeting in person or by proxy were holders of 9,356,252 shares of the Company’s common stock, representing 55.72% of the voting power of the shares of the Company’s common stock as of April 20, 2021, the record date for the Annual Meeting, and constituting a quorum for the transaction of business. The matters before the annual meeting are described in more detail in the Company’s definitive proxy statement filed with the United States Securities and Exchange Commission on April 30, 2021.

Proposal 1 – Election of Directors. The following nominees were elected as Class II directors to serve until the 2024 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified:

Nominee Votes For Votes Against Abstentions Broker Non-votes
Jim Allen 5,711,574 10,301 34,378 3,599,999
Andrew Scott Blank 5,586,904 126,965 42,384 3,599,999

Proposal 2 – Ratification of the Appointment of Independent Registered Public Accounting Firm. The appointment of PKF San Diego, LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2021 was ratified.

Votes For Votes Against Abstentions Broker Non-votes
9,245,321 67,899 43,032 ---

Proposal 3 – Approval, on an Advisory Basis, of the Company’s Executive Compensation. The Company’s executive compensation was approved on an advisory basis.

Votes For Votes Against Abstentions Broker Non-votes
5,649,192 91,505 15,556 3,599,999

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOCARDIA, INC.
/s/ Peter Altman, Ph.D.
Peter Altman, Ph.D.
President and Chief Executive Officer
Date: June 15, 2021